Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular Lymphoma

A learning opportunity provided by i3 Health has demonstrated significant knowledge gains and proficiency regarding the optimization of treating patients with relapsed/refractory (R/R) follicular lymphoma (FL). Non-Hodgkin lymphoma is one of the most prevalent cancers in the United States, with a 2022 estimate of around 80,470 people to be diagnosed, with 20,250 of these cases expected to be fatal. One in five of these cases will be FL, which is usually a slow-growing lymphoma but has the chance...

Continue reading

Copyright © 2022 Oncology Data Advisor. All rights reserved.